MedTrace Logo

Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery

NCT00226369 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 242

Last updated 2010-02-12

No results posted yet for this study

Summary

We conducted a multicenter, randomized, placebo-controlled trial of Cylexin, an inhibitor of the attachment of white blood cells to the endothelium. Our study population was neonates and infants undergoing hypothermic cardiopulmonary bypass during surgical repair or palliation of congenital heart defects.

Conditions

  • Congenital Heart Defects

Interventions

DRUG

CY-1503

Sponsors & Collaborators

Principal Investigators

  • Jane W Newburger, MD, MPH · Boston Children's Hospital

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Max Age
45 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-12-31
Completion
2001-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00226369 on ClinicalTrials.gov